Clausine E

CAS No. 182261-83-2

Clausine E( —— )

Catalog No. M23829 CAS No. 182261-83-2

Clausine E is an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 372 In Stock
5MG 361 In Stock
10MG 537 In Stock
25MG 846 In Stock
50MG 1144 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Clausine E
  • Note
    Research use only, not for human use.
  • Brief Description
    Clausine E is an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity.
  • Description
    Clausine E is an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity. The binding of Clausine E to FTO was driven by positive entropy and negative enthalpy changes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    FTO
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    182261-83-2
  • Formula Weight
    241.24
  • Molecular Formula
    C14H11NO3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC(c1cc(O)c2[nH]c(cccc3)c3c2c1)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wang Y, et al. Identification of Clausine E as an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity. J Mol Recognit. 2019 Oct;32(10):e2800.
molnova catalog
related products
  • Methylsyringin

    Methylsyringin exhibits anti-inflammatory activity in the LPS-stimulated RAW264.7 cells.

  • Neurogranin (30-45) ...

    Neurogranin 28-43 is a biological active peptide. (selective PKC substrate)

  • DB818

    DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.